Predictors of Response to Growth Hormone Treatment and Final Height in Medulloblastoma Survivors
Authors' conclusion
Growth retardation and GH deficiency are observed in the vast majority of medulloblastoma patients. Our results suggest that early identification and treatment of GH deficiency are crucial for optimization of FH outcome. Long-term safety of GHT is still a concern and should be discussed with the family prior to initiating treatment.
Study context
- Population
- Pediatric patients treated for medulloblastoma in a tertiary care center, 1987–2023, followed ≥1 year after diagnosis65 with growth retardation
- Participants
- 67 patients
- Exposure
- GH-treated vs not GH-treated medulloblastoma survivors
- GH-treatedn = 26
- Outcome
- Growth characteristics, response to GH treatment and factors associated with final height (FH) outcome
Methodological detailssingle tertiary care centre
- Single tertiary care centre
Main finding
As reported in the abstract
FH-SDS · final height
GH-treated
−1.42
mean · ± 1.47
Not GH-treated
−1.72
± 1.25
Lower without GH; difference not statistically significant
- Growth retardation
- 65/67 (97%)
- GH deficiency
- 38 (58%)
- GH-treated patients reaching final height (FH)
- 15
- GH-treated with FH within normal range
- 8 (53%)
Observational data: associations, not effects.
Original publication
Predictors of Response to Growth Hormone Treatment and Final Height in Medulloblastoma Survivors. Horm Res Paediatr. Published 11 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →